Mendus Logo

Mendus

Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.

IMMU | ST

Overview

Corporate Details

ISIN(s):
SE0005003654 (+1 more)
LEI:
529900AFBGFR7ZB50J95
Country:
Sweden
Address:
Västra Trädgårdsgatan 15, 111 53 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mendus is a clinical-stage biotechnology company dedicated to developing immunotherapies for cancer treatment. The company focuses on preventing tumor recurrence by stimulating the patient's immune system to build active immunity against residual cancer cells. Specializing in allogeneic dendritic cell biology, Mendus aims to improve long-term survival outcomes and preserve the quality of life for cancer patients. Its lead product candidate, vididencel, is under development for various malignancies, including ovarian cancer.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-28 08:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Mendus AB (publ)
Swedish 123.8 KB
2025-11-28 08:00
Declaration of Voting Results & Voting Rights Announcements
Change in number of shares and votes in Mendus AB (publ)
English 123.1 KB
2025-11-18 23:45
Pre-Annual General Meeting Information
Kallelse till extra bolagsstämma i Mendus AB (publ)
Swedish 145.4 KB
2025-11-18 23:45
Pre-Annual General Meeting Information
Notice of Extraordinary General Meeting in Mendus AB (publ)
English 147.5 KB
2025-11-18 23:41
Share Issue/Capital Change
Mendus har framgångsrikt genomfört en riktad nyemission om cirka 52,5 miljoner …
Swedish 151.0 KB
2025-11-18 23:41
Share Issue/Capital Change
Mendus announces successful execution of a directed share issue of approximatel…
English 150.6 KB
2025-11-18 17:31
Share Issue/Capital Change
Mendus avser att genomföra en riktad nyemission av aktier om cirka 50 miljoner …
Swedish 154.0 KB
2025-11-18 17:31
Share Issue/Capital Change
Mendus announces its intention to carry out a directed issue of shares of appro…
English 150.5 KB
2025-11-13 08:00
Quarterly Report
Swedish 1.5 MB
2025-11-13 08:00
Quarterly Report
English 1.5 MB
2025-11-06 08:00
Board/Management Information
Mendus Announces Nomination Committee for the 2026 Annual General Meeting
English 118.1 KB
2025-11-06 08:00
Board/Management Information
Mendus tillkännager valberedning inför årsstämman 2026
Swedish 118.2 KB
2025-10-02 08:00
Regulatory Filings
Mendus meddelar uppdaterad klinisk strategi och operativt fokus
Swedish 138.6 KB
2025-10-02 08:00
Regulatory Filings
Mendus announces updated clinical strategy and operational focus
English 137.5 KB
2025-08-21 08:00
Quarterly Report
Swedish 1.4 MB

Automate Your Workflow. Get a real-time feed of all Mendus filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mendus

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mendus via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-11 Erik Manting Other Buy 7,780 56,249.40 SEK
2025-03-11 Erik Manting Other Buy 7,780 55,704.80 SEK
2025-02-25 Sven Arne Andreasson Other Buy 25,000 198,750.00 SEK
2024-04-02 Erik Manting Other Other 885,648 425,111.04 SEK
2024-04-02 Dharminder Chahal Other Other 882,048 423,383.04 SEK
2024-04-02 Leopold Bertea Other Other 267,858 128,571.84 SEK
2022-10-25 Sven Arne Andreasson Other Sell 15,000 31,950.00 SEK
2022-10-12 Sven Arne Andreasson Other Sell 10,000 18,800.00 SEK
2022-05-20 Erik Manting Other Buy 37,059 86,347.47 SEK
2022-05-19 Ann-Charlotte Ferm Other Buy 100,000 215,900.00 SEK

Peer Companies

ALNYLAM PHARMACEUTICALS, INC. Logo
Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.
United States of America
ALNY
Alpha Cognition Inc. Logo
Develops and commercializes novel treatments for neurodegenerative diseases like Alzheimer's and ALS.
United States of America
ACOG
Alpha Teknova, Inc. Logo
Manufactures critical reagents for biopharma, scaling from research to GMP manufacturing.
United States of America
TKNO
ALTERITY THERAPEUTICS LTD Logo
Developing therapies for Parkinsonian disorders and MSA by inhibiting protein aggregation.
United States of America
ATHE
Altimmune, Inc. Logo
Developing novel peptide therapeutics for obesity, liver, and cardiometabolic diseases.
United States of America
ALT
Alto Neuroscience, Inc. Logo
Developing precision medicines for depression and schizophrenia using a brain biomarker platform.
United States of America
ANRO
ALUMIS INC. Logo
Develops targeted oral therapies for immune-mediated diseases using precision immunology.
United States of America
ALMS
Alvotech Holdings S.A Logo
Develops and manufactures affordable biosimilar medicines for global patient access.
Luxembourg
ALVO
ALX ONCOLOGY HOLDINGS INC Logo
Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.
United States of America
ALXO
Alzamend Neuro, Inc. Logo
Developing lithium & vaccine therapies for neurodegenerative & psychiatric disorders.
United States of America
ALZN

Talk to a Data Expert

Have a question? We'll get back to you promptly.